RAS: Past, Present, and Future
Advances in Cancer Research, volume 153 provides a timely review of the biology, biochemistry, and current approaches to therapeutically target the RAS oncoprotein, the most frequently mutated oncogene family in human cancers. 2021 saw the approval of the first direct RAS inhibitor (sotorasib) for u...
Gespeichert in:
| Format: | Buch |
|---|---|
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | 153 |
| description | Advances in Cancer Research, volume 153 provides a timely review of the biology, biochemistry, and current approaches to therapeutically target the RAS oncoprotein, the most frequently mutated oncogene family in human cancers. 2021 saw the approval of the first direct RAS inhibitor (sotorasib) for use in treating non-small cell lung cancers harboring KRAS(G12C) mutations. The successful approval and use of this drug highlights that the once "undruggable? RAS is indeed pharmacologically tractable. This volume provides an overview of efforts to develop additional approaches to therapeutically target oncogenic RAS. In addition, the reader will find excellent reviews on the history and research efforts to understand the biochemistry and oncogenic activity of RAS in human cancers. |
| format | Book |
| fullrecord | <record><control><sourceid>askewsholts</sourceid><recordid>TN_cdi_askewsholts_vlebooks_9780128244869</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>9780128244869</sourcerecordid><originalsourceid>FETCH-LOGICAL-a8719-32a70173bddbde80a23ed93723a4a87421b081377f403f5416604597c0b36fd03</originalsourceid><addsrcrecordid>eNpVj8sKwjAQReNCULS_IN0KFiaZtEncifiCguJjXRKTIrZYcKr-voJuXN2zOBy4HRYZpYELLaTUmemxiOgKAMhT0IB9NtrPDtN4Z6mdxLt7oHD7gL35ePloH_cwZN3S1hSi3w7Yabk4ztdJvl1t5rM8sVpxk6CwCrhC573zQYMVGLxBJdDKjyEFd6A5KlVKwDKVPMtApkadwWFWesABG3-7lqrwoktTt1Q86-CapqLi7wO-AWobOF8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>book</recordtype></control><display><type>book</type><title>RAS: Past, Present, and Future</title><source>ScienceDirect eBooks</source><description>Advances in Cancer Research, volume 153 provides a timely review of the biology, biochemistry, and current approaches to therapeutically target the RAS oncoprotein, the most frequently mutated oncogene family in human cancers. 2021 saw the approval of the first direct RAS inhibitor (sotorasib) for use in treating non-small cell lung cancers harboring KRAS(G12C) mutations. The successful approval and use of this drug highlights that the once "undruggable? RAS is indeed pharmacologically tractable. This volume provides an overview of efforts to develop additional approaches to therapeutically target oncogenic RAS. In addition, the reader will find excellent reviews on the history and research efforts to understand the biochemistry and oncogenic activity of RAS in human cancers.</description><identifier>EISBN: 9780128244869</identifier><identifier>EISBN: 0128244860</identifier><language>eng</language><publisher>Academic Press</publisher><creationdate>2022</creationdate><tpages>356</tpages><format>356</format><woscitedreferencessubscribed>false</woscitedreferencessubscribed><relation>Advances in Cancer Research</relation></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>306,778,782,784,24767</link.rule.ids></links><search><title>RAS: Past, Present, and Future</title><description>Advances in Cancer Research, volume 153 provides a timely review of the biology, biochemistry, and current approaches to therapeutically target the RAS oncoprotein, the most frequently mutated oncogene family in human cancers. 2021 saw the approval of the first direct RAS inhibitor (sotorasib) for use in treating non-small cell lung cancers harboring KRAS(G12C) mutations. The successful approval and use of this drug highlights that the once "undruggable? RAS is indeed pharmacologically tractable. This volume provides an overview of efforts to develop additional approaches to therapeutically target oncogenic RAS. In addition, the reader will find excellent reviews on the history and research efforts to understand the biochemistry and oncogenic activity of RAS in human cancers.</description><isbn>9780128244869</isbn><isbn>0128244860</isbn><fulltext>true</fulltext><rsrctype>book</rsrctype><creationdate>2022</creationdate><recordtype>book</recordtype><sourceid/><recordid>eNpVj8sKwjAQReNCULS_IN0KFiaZtEncifiCguJjXRKTIrZYcKr-voJuXN2zOBy4HRYZpYELLaTUmemxiOgKAMhT0IB9NtrPDtN4Z6mdxLt7oHD7gL35ePloH_cwZN3S1hSi3w7Yabk4ztdJvl1t5rM8sVpxk6CwCrhC573zQYMVGLxBJdDKjyEFd6A5KlVKwDKVPMtApkadwWFWesABG3-7lqrwoktTt1Q86-CapqLi7wO-AWobOF8</recordid><startdate>20220201</startdate><enddate>20220201</enddate><general>Academic Press</general><scope/></search><sort><creationdate>20220201</creationdate><title>RAS: Past, Present, and Future</title></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a8719-32a70173bddbde80a23ed93723a4a87421b081377f403f5416604597c0b36fd03</frbrgroupid><rsrctype>books</rsrctype><prefilter>books</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>online_resources</toplevel></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><format>book</format><genre>book</genre><ristype>BOOK</ristype><btitle>RAS: Past, Present, and Future</btitle><seriestitle>Advances in Cancer Research</seriestitle><date>2022-02-01</date><risdate>2022</risdate><volume>153</volume><eisbn>9780128244869</eisbn><eisbn>0128244860</eisbn><abstract>Advances in Cancer Research, volume 153 provides a timely review of the biology, biochemistry, and current approaches to therapeutically target the RAS oncoprotein, the most frequently mutated oncogene family in human cancers. 2021 saw the approval of the first direct RAS inhibitor (sotorasib) for use in treating non-small cell lung cancers harboring KRAS(G12C) mutations. The successful approval and use of this drug highlights that the once "undruggable? RAS is indeed pharmacologically tractable. This volume provides an overview of efforts to develop additional approaches to therapeutically target oncogenic RAS. In addition, the reader will find excellent reviews on the history and research efforts to understand the biochemistry and oncogenic activity of RAS in human cancers.</abstract><pub>Academic Press</pub><tpages>356</tpages></addata></record> |
| fulltext | fulltext |
| identifier | EISBN: 9780128244869 |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_askewsholts_vlebooks_9780128244869 |
| source | ScienceDirect eBooks |
| title | RAS: Past, Present, and Future |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T03%3A03%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-askewsholts&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=book&rft.btitle=RAS:%20Past,%20Present,%20and%20Future&rft.date=2022-02-01&rft.volume=153&rft_id=info:doi/&rft_dat=%3Caskewsholts%3E9780128244869%3C/askewsholts%3E%3Curl%3E%3C/url%3E&rft.eisbn=9780128244869&rft.eisbn_list=0128244860&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |